Analyst Price Targets — BEAM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 21, 2026 10:39 am | Patrick Trucchio | H.C. Wainwright | $80.00 | $27.11 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM) |
| May 13, 2026 10:27 am | William Pickering | Tudor Pickering | $39.00 | $31.58 | TheFly | Beam Therapeutics price target lowered to $39 from $40 at Bernstein |
| February 25, 2026 2:20 pm | — | RBC Capital | $26.00 | $30.83 | TheFly | Beam Therapeutics price target raised to $26 from $22 at RBC Capital |
| February 20, 2026 11:29 am | — | Canaccord Genuity | $74.00 | $27.88 | TheFly | Beam Therapeutics initiated with a Buy at Canaccord |
| January 21, 2026 12:44 pm | William Pickering | Tudor Pickering | $41.00 | $31.00 | StreetInsider | Beam Therapeutics Inc (BEAM) PT Raised at Bernstein Following Positive Regulatory Update |
| January 20, 2026 11:44 pm | — | Bernstein | $41.00 | $30.97 | TheFly | Beam Therapeutics price target raised to $41 from $37 at Bernstein |
| January 7, 2026 5:40 am | Michael Yee | UBS | $28.00 | $28.34 | StreetInsider | UBS Starts Beam Therapeutics Inc (BEAM) at Neutral |
| November 24, 2025 1:11 pm | — | Evercore ISI | $35.00 | $23.32 | TheFly | Beam Therapeutics initiated with an Outperform at Evercore ISI |
| October 9, 2025 3:43 pm | — | Jefferies | $41.00 | $27.86 | TheFly | Beam Therapeutics initiated with a Buy at Jefferies |
| May 7, 2025 12:18 pm | Debjit Chattopadhyay | Guggenheim | $55.00 | $15.99 | TheFly | Beam Therapeutics price target lowered to $55 from $78 at Guggenheim |
Latest News for BEAM
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam's commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease…
CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BEAM.
U.S. House Trading
No House trades found for BEAM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.